We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Spectral Medical Inc.
EDTXF 0.370-0.9%Jul 18 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Sultan5/6/2024 11:57:07 AM
   of 473
Spectral Medical Provides April Tigris Trial Update

Spectral Medical Inc.
Mon, May 6, 2024, 4:30 AM PDT3 min read

• 105 patients enrolled

• April represents a record breaking month for patient enrollment

TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.


  • Robust enrollment activity continuing throughout 2024:

    • 105 patients enrolled at end of April 2024

      • Record monthly enrollment with seven patients enrolled in April

      • 24 patients enrolled in 2024 so far – represents the most robust enrollment rates since the start of the Tigris study

  • With 45 patients to full enrollment, the Company is entering the final push to fully enroll and finish the Tigris trial

    • To support sustained enrollment, Spectral hosted an in-person Investigator Meeting March 12th & 13th in conjunction with the 29th International Conference on Advances in Critical Care Nephrology in San Diego

    • In-person meeting well attended with multiple stakeholders present, including: principal investigators and clinical research coordinators from existing and new trial sites; CRO, Beaufort; and representatives from the Company’s strategic partner Baxter

Trial Sites:

  • Continued progress opening additional high quality clinical sites

    • Recently onboarded the University of Virginia

    • Two pending sites in the pipeline finalizing contracting and training

    • Spectral clinical team focused on trial site management activities to ensure that Tigris sites have the support and resources to enroll patients as efficiently as possible

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext